RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07492615, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Diagnosed with mismatch repair deficiency (dMMR) by immunohistochemistry (IHC) of biopsy tissue or microsatellite instability-high (MSI-H) by genetic sequencing.

    Inclusion criterion 5

  3. Unstable angina, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) class ≥2.

    Exclusion criterion 20

  4. For female subjects of childbearing potential, a urine or serum pregnancy test must be negative within 3 days prior to the first dose of study drug (Cycle 1 Day 1). If the urine pregnancy test cannot be confirmed as negative, a serum pregnancy test is required. Non-childbearing potential is defined as postmenopausal for at least 1 year, or surgically sterile or hysterectomy.

    Inclusion criterion 20

    If at risk of conception, all subjects (male or female) must use contraceptive measures with a failure rate of <1% per year throughout the treatment period and for 120 days after the last dose of study drug (or 180 days after the last dose of chemotherapy).

    Inclusion criterion 21

    Currently participating in interventional clinical study treatment, or has received other investigational drugs or used investigational devices within 4 weeks prior to first dose.

    Exclusion criterion 3

    Prior receipt of the following therapies: anti-PD-1, anti-PD-L1, or drugs targeting another stimulatory or co-inhibitory T-cell receptor (including but not limited to CTLA-4, OX-40, CD137, etc.).

    Exclusion criterion 4

    Received systemic therapy with Chinese patent medicines with anti-tumor indications or immunomodulatory drugs (including thymosin, interferons, interleukins, except for local use to control pleural effusion) within 2 weeks prior to first dose.

    Exclusion criterion 5

    Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to first dose. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment.

    Exclusion criterion 6

    Has not adequately recovered from toxicities and/or complications caused by any prior intervention prior to starting treatment (i.e., ≤ grade 1 or returned to baseline, excluding fatigue or alopecia).

    Exclusion criterion 10

    HBV viral load <1000 copies/ml (200 IU/ml) prior to first dose, subjects should receive anti-HBV therapy during the entire study chemotherapy treatment to prevent reactivation.

    Exclusion criterion 13

  5. ECOG performance status 0-1.

    Inclusion criterion 8

  6. Absolute neutrophil count (ANC) ≥1.5×10\^9/L without granulocyte colony-stimulating factor within the past 14 days.

    Inclusion criterion 11

    Platelets ≥100×10\^9/L without transfusion within the past 14 days.

    Inclusion criterion 12

    Hemoglobin >9 g/dL without transfusion or erythropoietin use within the past 14 days.

    Inclusion criterion 13

    Total bilirubin ≤1.5×ULN; if total bilirubin >1.5×ULN but direct bilirubin ≤ULN, enrollment is also permitted.

    Inclusion criterion 14

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN.

    Inclusion criterion 15

    Serum creatinine ≤1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥60 ml/min.

    Inclusion criterion 16

  7. Diagnosis of any other malignant disease other than gastric cancer within 5 years prior to first dose (excluding curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or curatively resected carcinoma in situ).

    Exclusion criterion 2

    Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive).

    Exclusion criterion 11

    For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-) and HBV viral load (-), prophylactic anti-HBV therapy is not required, but close monitoring for viral reactivation is needed.

    Exclusion criterion 14

    Subjects with active HCV infection (HCV antibody positive and HCV-RNA level above the lower limit of detection).

    Exclusion criterion 15

  8. Pregnant or breastfeeding women.

    Exclusion criterion 17

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07492615, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Signed written informed consent.
  • Male or female, age ≥18 years.
  • Histopathologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEJ).
  • Diagnosed with pTNM stage IIIC or pTNM stage IIIA/IIIB.
  • Diagnosed with mismatch repair deficiency (dMMR) by immunohistochemistry (IHC) of biopsy tissue or microsatellite instability-high (MSI-H) by genetic sequencing.
  • Underwent D2 or more extensive radical resection and achieved R0 resection.
  • Able to swallow tablets normally.
  • ECOG performance status 0-1.
  • Life expectancy >6 months.
  • Adequate organ function, subjects must meet the following laboratory criteria:
  • Absolute neutrophil count (ANC) ≥1.5×10\^9/L without granulocyte colony-stimulating factor within the past 14 days.
  • Platelets ≥100×10\^9/L without transfusion within the past 14 days.
  • Hemoglobin >9 g/dL without transfusion or erythropoietin use within the past 14 days.
  • Total bilirubin ≤1.5×ULN; if total bilirubin >1.5×ULN but direct bilirubin ≤ULN, enrollment is also permitted.
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN.
  • Serum creatinine ≤1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥60 ml/min.
  • Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN.
  • Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within normal range. If baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range may also be enrolled.
  • Cardiac enzyme panel within normal range (isolated laboratory abnormalities deemed clinically insignificant by the investigator are also permitted for enrollment).
  • For female subjects of childbearing potential, a urine or serum pregnancy test must be negative within 3 days prior to the first dose of study drug (Cycle 1 Day 1). If the urine pregnancy test cannot be confirmed as negative, a serum pregnancy test is required. Non-childbearing potential is defined as postmenopausal for at least 1 year, or surgically sterile or hysterectomy.
  • If at risk of conception, all subjects (male or female) must use contraceptive measures with a failure rate of <1% per year throughout the treatment period and for 120 days after the last dose of study drug (or 180 days after the last dose of chemotherapy).

Exclusion Criteria:

  • Cancers involving the EGJ with the tumor center located in the proximal stomach ≤2 cm from the EGJ.
  • Diagnosis of any other malignant disease other than gastric cancer within 5 years prior to first dose (excluding curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or curatively resected carcinoma in situ).
  • Currently participating in interventional clinical study treatment, or has received other investigational drugs or used investigational devices within 4 weeks prior to first dose.
  • Prior receipt of the following therapies: anti-PD-1, anti-PD-L1, or drugs targeting another stimulatory or co-inhibitory T-cell receptor (including but not limited to CTLA-4, OX-40, CD137, etc.).
  • Received systemic therapy with Chinese patent medicines with anti-tumor indications or immunomodulatory drugs (including thymosin, interferons, interleukins, except for local use to control pleural effusion) within 2 weeks prior to first dose.
  • Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to first dose. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment.
  • Receiving systemic corticosteroid therapy (excluding nasal spray, inhaled, or other topical corticosteroids) or any other form of immunosuppressive therapy within 7 days prior to first dose.
  • Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.
  • Known allergy to any drug used in this study.
  • Has not adequately recovered from toxicities and/or complications caused by any prior intervention prior to starting treatment (i.e., ≤ grade 1 or returned to baseline, excluding fatigue or alopecia).
  • Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive).
  • Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number above the upper limit of normal of the testing laboratory at the study site). Subjects meeting the following criteria may also be enrolled:
  • HBV viral load <1000 copies/ml (200 IU/ml) prior to first dose, subjects should receive anti-HBV therapy during the entire study chemotherapy treatment to prevent reactivation.
  • For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-) and HBV viral load (-), prophylactic anti-HBV therapy is not required, but close monitoring for viral reactivation is needed.
  • Subjects with active HCV infection (HCV antibody positive and HCV-RNA level above the lower limit of detection).
  • Received a live vaccine within 30 days prior to first dose (Cycle 1, Day 1).
  • Pregnant or breastfeeding women.
  • Presence of any severe or uncontrolled systemic disease, such as:
  • Abnormalities in resting ECG in rhythm, conduction, or morphology that are significant and severely symptomatic and difficult to control, such as complete left bundle branch block, second-degree or higher heart block, ventricular arrhythmias, or atrial fibrillation.
  • Unstable angina, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) class ≥2.
  • Any arterial thrombotic, embolic, or ischemic event within 6 months prior to enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack.
  • Uncontrolled hypertension (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg).
  • History of non-infectious pneumonitis requiring corticosteroid treatment within 1 year prior to first dose, or current clinically active interstitial lung disease.
  • Active pulmonary tuberculosis.
  • Active or uncontrolled infection requiring systemic therapy.
  • Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction.
  • Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis.
  • Poorly controlled diabetes (fasting blood glucose (FBG) >10 mmol/L).
  • Urinalysis indicates proteinuria ≥++ and confirmed 24-hour urine protein quantification >1.0 g.
  • Patients with mental disorders who are unable to comply with treatment.
  • History or evidence of disease, treatment, or laboratory abnormalities that may interfere with the study results, hinder the subject's full participation in the study, or other conditions that the investigator deems unsuitable for enrollment, or the investigator believes there are other potential risks that make participation inappropriate.

Quoted from ClinicalTrials.gov, NCT07492615, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07492615, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07492615